BTIG Reiterates Buy on Cullinan Therapeutics, Maintains $40 Price Target
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsReiterationPrice Target
BTIG analyst Julian Harrison reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and maintains $40 price target.
BTIG analyst Julian Harrison reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and maintains $40 price target.